|
| |
CTLA4
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 17970696 |
The increase in Fas and CTLA4 molecules in multiple sclerosis patients may lead to lymphocyte apoptosis, which suggests possible mechanisms underlying the therapeutic response to IFN-beta. |
| 18093182 |
CTLA-4 gene, CT60A>G and +49A>G SNPs were studied in psoriasis vulgaris patients; the haplotype +49G, CT60G was significantly less frequent in the patient group with disease onset between the ages of 21 and 40 years than in controls. |
| 18200060 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18223493 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18282809 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18292106 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18292987 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18296657 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18328194 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18337305 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | →View more information from publications. |
Recent Publications on CTLA4: |  |
Recent progress in the genetics of Wegener's granulomatosis and Churg-Strauss syndrome.
PURPOSE OF REVIEW: Recently, numerous studies have been performed to... | 30th October, 2009
| aRuhr-University, Human Genetics, Bochum, Germany bDepartment of
| Curr Opin Rheumatol. 2009 Oct 27.
DOI Direct Link |
Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
To explore the role of proline-rich tyrosine kinase 2 (PYK2) in systemic... | 28th October, 2009
| Department of Rheumatology and Immunology, Provincial Hospital Affiliated
| Hybridoma (Larchmt). 2009 Oct;28(5):333-9.
DOI Direct Link |
[Influence of genetic factors on development and severity of rheumatoid arthritis--part I]
Both genetic and environmental factors affect susceptibility, severity and... | 28th October, 2009
| Institute of Rheumatology in Warsaw, Department of Systemic Connective
| Pol Merkur Lekarski. 2009 Aug;27(158):157-60.
|
Association and interaction analyses of eight genes under asthma linkage peaks.
BACKGROUND: Linkage studies have implicated the 2q33, 9p21, 11q13 and... | 15th October, 2009
| Queensland Institute of Medical Research, Brisbane, Australia.
| Allergy. 2009 Nov;64(11):1623-8.
DOI Direct Link |
Lentiviral gene transfer of CTLA4 generates B cells with reduced costimulatory properties.
Peripheral T-cell (TC) tolerance can be induced by tolerogenic... | 9th October, 2009
| Genethor GmbH, Goltz Strasse 52, 10781, Berlin, Germany.
| Autoimmunity. 2009 May;42(4):380-2.
|
→View more research publications. |
Press Releases on CTLA4:
|
 |
| New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel |
6th November, 2009 |
MedPredict |
-- Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk,
TNF/PDE4, BTK, MEK, and S1P.
Companies/Partnerships mentioned in this report include: Abbott
|
| BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) |
25th February, 2009 |
BN ImmunoTherapeutics |
MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN
ImmunoTherapeutics, Inc. announced today that the first detailed data on
PROSTVAC(TM) since the vaccine was licensed from the National
|
| Bavarian Nordic Reports Further Data on PROSTVAC(TM) |
25th February, 2009 |
|
KVISTGAARD, Denmark, February 25 /PRNewswire/ -- Bavarian Nordic today announced that the first detailed data on
PROSTVAC(TM) since the vaccine was licensed from the National Institutes of
Health
|
| Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer |
24th November, 2008 |
Medarex, Inc. |
PRINCETON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono
|
| Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology |
4th September, 2008 |
Medarex, Inc. |
PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that nine clinical abstracts for ipilimumab, an
investigational anti-CTLA-4 antibody, in melanoma
|
CTLA4 results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for CTLA4,
or search for CTLA4 on BioPortfolio's antibody search engine.
This page has been viewed 507 times
Recent Search Terms used to find this page: CTLA-4-FITC | ctla4 2009 | Cytotoxic T lymphocyte | Cytotoxic T-lymphocyte protein 4 | is ctla4 promising 2009 | Th17 2009 cytotoxic | elisa ctla-4 | ctla4 2009 | 09 ctla4 clinical trial | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
